Evicenter
P&T meetings

Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer
Exelixis
Regulatory submission
NDA submitted December 2025
Launch
Not announced
Last updated
65 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic colorectal cancer

Humanistic burden and health-related quality of life

3 evidence topics · 3 sources

Comparator and disease-state studies: third-line treatment decision-making among community physicians

“Overall survival (OS) and impacts to patient quality of life (QoL) were primary considerations for any third-line treatment for mCRC.” (opens the source at this quote in a new tab)

Comparator and disease-state studies: SUNLIGHT health-related quality of life and performance status

“Both treatment arms showed similar QoL scores from baseline to cycle 6, with no clinically relevant change over time.” (opens the source at this quote in a new tab)

Comparator and disease-state studies: FRESCO-2 quality-adjusted survival

“Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC.” (opens the source at this quote in a new tab)